Document is current
Any future updates will be listed below
-
Authors
Pan, Yiheng
Davis, Pamela B.
Kaebler, David C.
Blankfield, Robert P.
Xu, Rong
-
Funding
Funding for this research was provided by:
National Institute on Aging (AG057557, AG061388, AG062272, AG076649)
National Institute on Alcohol Abuse and Alcoholism (AA029831)
the Clinical and Translational Science Collaborative (CTSC) of Cleveland (TR002548)
National Cancer Institute Case Comprehensive Cancer Center (CA221718, CA043703, CA2332216)
- License Information
-
More Information
Article History
Received: 22 July 2022
Accepted: 24 August 2022
First Online: 1 September 2022
Declarations
:
: The MetroHealth System, Cleveland, Ohio, institutional review board has determined that any research using TriNetX is not human participants research and therefore is exempt from institutional review board review.
: Not applicable.
: RPB has a patent for the concept that one can use markers of fluid retention to gauge the cardiovascular risk of a drug. No other disclosures were reported.
